Oh, S., Yeom, J., Cho, H. J., Kim, J., Yoon, S., Kim, H., . . . Kim, H. S. (2020). Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities. Nature Portfolio.
Cita Chicago Style (17a ed.)Oh, Sejin, et al. Integrated Pharmaco-proteogenomics Defines Two Subgroups in Isocitrate Dehydrogenase Wild-type Glioblastoma with Prognostic and Therapeutic Opportunities. Nature Portfolio, 2020.
Cita MLA (8a ed.)Oh, Sejin, et al. Integrated Pharmaco-proteogenomics Defines Two Subgroups in Isocitrate Dehydrogenase Wild-type Glioblastoma with Prognostic and Therapeutic Opportunities. Nature Portfolio, 2020.
Precaución: Estas citas no son 100% exactas.